NamibiaTuberculosis profile
Population  2014 2.4 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.5 (1.1–2) 63 (45–83)
Mortality (HIV+TB only) 1.5 (1.2–1.9) 64 (51–79)
Prevalence  (includes HIV+TB) 15 (8.5–23) 627 (353–978)
Incidence  (includes HIV+TB) 13 (12–15) 561 (492–635)
Incidence (HIV+TB only) 5.6 (4.8–6.5) 232 (198–269)
         
Case detection, all forms (%) 68 (60–77)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 3.8 (2.7–5.1) 16 (13–21)
MDR-TB cases among notified pulmonary
TB cases
240 (170–330) 340 (260–430)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 4 420   1 133
Pulmonary, clinically diagnosed 2 000    
Extrapulmonary 1 561    
       
Total new and relapse 9 114    
Previously treated, excluding relapses 935    
Total cases notified 10 049    
Among 8 842 new cases:
877 (10%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB      
Laboratory-confirmed RR-/MDR-TB cases     350
Patients started on MDR-TB treatment ***     327
TB/HIV 2014 Number (%)
TB patients with known HIV status 9 088 (90)
HIV-positive TB patients 3 994 (44)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 3 940 (99)
HIV-positive TB patients on antiretroviral therapy (ART) 3 360 (84)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (86) 8 418
Previously treated cases registered in 2013 (71) 2 192
HIV-positive TB cases, all types, registered in 2013 (81) 4 343
RR-/MDR-TB cases started on second-line treatment in 2012 (68) 208
XDR-TB cases started on second-line treatment in 2012 (20) 5
Laboratories 2014  
Smear (per 100 000 population) 1.2
Culture (per 5 million population) 2.1
Drug susceptibility testing (per 5 million population) 2.1
Sites performing Xpert MTB/RIF 22
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 34
% Funded domestically 48%
% Funded internationally 16%
% Unfunded 36%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-09-29 Data: www.who.int/tb/data